Business Wire

KIRIN-HOLDINGS

5.8.2022 04:02:10 CEST | Business Wire | Press release

Share
Kirin Holdings’ Long-term GHG Reduction Target Was Approved by the Science Based Targets*1 Initiative Based on Science-based Net-zero Targets

Kirin Holdings Company, Limited (Kirin Holdings) has been approved as the first world company in the food and beverage processing sector with science-based net-zero targets validated by SBTi * 2 in July 2022. The Kirin Group’s long-term GHG reduction target , "realizing net-zero* 3 GHG* 4 emission from the entire value chain by 2050" set forth in the Kirin Group Environmental Vision 2050 was certified as a scientifically based goal consistent with the level of GHG emission reductions required by the Paris Agreement* 5 .

Kirin Holdings, with the aim of becoming " A global leader in CSV* 6 ”, have declared our goal of achieving net-zero emissions by 2020 under the Kirin Group Environmental Vision 2050 and have formulated a roadmap for achieving the goal, which went into operation in January 2022.

A sense of crisis was shared around the world on the issue of climate change in the wake of the 2015 Paris Agreement, the 2018 IPCC 1.5°C Special Report* 7 reported that global warming from pre-industrial times must be limited to 1.5°C and GHG emissions must be reduced to net zero by around 2050. In order to achieve that common global long-term goal, many companies in the world have set "2050 Net Zero" targets. However, since there is no common standard for corporate net-zero targets, the scope of GHG emissions to be covered, the means to achieve net-zero, and the level of GHG reductions differ, and thus a divergence from the target needed to limit global warming to 1.5°C has been pointed out.

In response to this flurry of net-zero targets, the SBT Initiative developed the "Net Zero Standard" in October 2021. This standard stipulates that in order to limit global warming to 1.5°C, companies must reduce GHG emissions by at least 90% across their value chains by 2050, and the net-zero can be achieved by removing the remaining 10% of GHG emissions from the atmosphere.

In order to achieve The Kirin Group’s long-term goal, Kirin Holdings has set a mid-term target for 2030 (to reduce the total of Scope 1 and Scope 2 for the entire group by 50% and Scope 3 by 30% by 2030 compared to 2019), and is promoting GHG reduction in our value chain with the technological capabilities we have cultivated over the years. For Scope 1 and Scope 2, we have installed heat pumps at six Kirin Brewery breweries in Japan, utilizing our plant engineering capabilities to reduce GHG emissions by approximately 3,800 tons per year. In terms of Scope 3, we are gradually expanding the use of "R100 PET bottles" made of 100% recycled PET resin, and are rolling them out for some of our Kirin Nama-cha brands.

With the goal of achieving net zero emissions by 2050, Kirin Holdings will continue to work toward the realization of the Kirin Group Environmental Vision 2050, which aims to strengthen the resilience of society and the company, and to lead the way toward the creation of a decarbonized society.

1:

Science Based Targets: Greenhouse gas reduction targets based on scientific evidence.

2:

An international initiative jointly established in 2015 by CDP, the UN Global Compact, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).

3:

A state in which anthropogenic GHG emissions and removals are balanced and GHG emissions to the atmosphere are net zero.

4:

Green House Gas

5:

International framework for global warming countermeasures in which all countries and regions participate

6:

Creating Shared Value. Combined added value for consumers as well as for society at large.

7:

This report published by the Intergovernmental Panel on Climate Change (IPCC) describes the significant difference between 2°C and 1.5°C in terms of the impact of future temperature increases and the emission pathways to limit the increase to 1.5°C.

[Reference]
・Kirin Group Environmental Vision 2050
https://www.kirinholdings.com/en/impact/env/mission/

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye